Spasmodic dysphonia: Onset, course, socioemotional effects, and treatment response

Annals of Otology, Rhinology and Laryngology

Volumn 120, Issue 7, 2011, Pages 465-473

  Tanner, Kristine ^a,b   Roy, Nelson ^a,b   Merrill, Ray M ^c   Sauder, Cara ^a   Houtz, Daniel R ^a   Smith, Marshall E ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Ansa cervicalis reinnervation; Botox; Botulinum toxin A; Recurrent laryngeal nerve denervation; Spasmodic dysphonia; V RQOL; Voice disorder; Voice related quality of life

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT LARYNGEAL NERVE; REINNERVATION; SHORT FORM 36; SOCIOECONOMICS; SPASMODIC DYSPHONIA; SPEECH THERAPY; TREATMENT RESPONSE; VOICE RELATED QUALITY OF LIFE QUESTIONNAIRE;

EID: 79960153410     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348941112000708     Document Type: Article

References (51)

1. Bloch CS, Hirano M, Gould WJ. Symptom improvement of spastic dysphonia in response to phonatory tasks. Ann Otol Rhinol Laryngol 1985;94:51-4. (Pubitemid 15135213)
2. Roy N, Gouse M, Mauszycki S, Merrill RM, Smith ME. Task specificity in adductor spasmodic dysphonia versus muscle tension dysphonia. Laryngoscope 2005;115:311-6. (Pubitemid 40216710)
3. Roy N, Mauszycki SC, Merrill RM, Gouse M, Smith ME. Toward improved differential diagnosis of adductor spasmodic dysphonia and muscle tension dysphonia. Folia Phoniatr Logop 2007;59:83-90. (Pubitemid 46340917)
4. Simonyan K, Tovar-Moll F, Ostuni J, et al. Focal white matter changes in spasmodic dysphonia: a combined diffusion tensor imaging and neuropathological study. Brain 2008;131:447-59. (Pubitemid 351197613)
5. Edgar JD, Sapienza CM, Bidus K, Ludlow CL. Acoustic measures of symptoms in abductor spasmodic dysphonia. J Voice 2001;15:362-72. (Pubitemid 32889296)
6. Ludlow CL. Laryngeal movement disorders: treatment with botulinum toxin. In: Kent RD, ed. The MIT encyclopedia of communication disorders. Cambridge, Mass: The MIT Press, 2004:38-41.
7. Ludlow CL. Treatment for spasmodic dysphonia: limitations of current approaches. Curr Opin Otolaryngol Head Neck Surg 2009;17:160-5.
8. Aronson AE, Brown JR, Litin EM, Pearson JS. Spastic dysphonia. II. Comparison with essential (voice) tremor and other neurologic and psychogenic dysphonias. J Speech Hear Disord 1968;33:219-31.
9. Brodnitz FS. Spastic dysphonia. Ann Otol Rhinol Laryngol 1976;85:210-4.
10. Aronson AE. Clinical voice disorders: an interdisciplinary approach. 3rd ed. New York, NY: Thieme, 1990.
11. Schaefer SD. Neuropathology of spasmodic dysphonia. Laryngoscope 1983;93:1183-204. (Pubitemid 13001672)
12. Izdebski K, Dedo HH, Boles L. Spastic dysphonia: a patient profile of 200 cases. Am J Otolaryngol 1984;5:7-14. (Pubitemid 14009071)
13. Bhattacharyya N, Tarsy D. Impact on quality of life of botulinum toxin treatments for spasmodic dysphonia and oromandibular dystonia. Arch Otolaryngol Head Neck Surg 2001;127:389-92. (Pubitemid 32299012)
14. Benninger MS, Gardner G, Grywalski C. Outcomes of botulinum toxin treatment for patients with spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 2001;127:1083-5. (Pubitemid 32848185)
15. Braden MN, Johns MM III, Klein AM, Delgaudio JM, Gilman M, Hapner ER. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception. J Voice 2010;24:242-9.
16. Hogikyan ND, Wodchis WP, Spak C, Kileny PR. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001;15:576-86. (Pubitemid 33151976)
17. Paniello RC, Barlow J, Serna JS. Longitudinal follow-up of adductor spasmodic dysphonia patients after botulinum toxin injection: quality of life results. Laryngoscope 2008;118:564-8. (Pubitemid 351640641)
18. Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004;130:415-20. (Pubitemid 38456315)
19. Wingate JM, Ruddy BH, Lundy DS, et al. Voice handicap index results for older patients with adductor spasmodic dysphonia. J Voice 2005;19:124-31. (Pubitemid 40342781)
20. Dedo HH. Recurrent laryngeal nerve section for spastic dysphonia. Ann Otol Rhinol Laryngol 1976;85:451-9.
21. Biller HF, Som ML, Lawson W. Laryngeal nerve crush for spastic dysphonia. Ann Otol Rhinol Laryngol 1979;88:531-2. (Pubitemid 9255210)
22. Netterville JL, Stone RE, Rainey C, Zealear DL, Ossoff RH. Recurrent laryngeal nerve avulsion for treatment of spastic dysphonia. Ann Otol Rhinol Laryngol 1991;100:10-4.
23. Shiratzki H, Fritzell B. Treatment of spasmodic dysphonia by means of resection of the recurrent laryngeal nerve. Acta Otolaryngol Suppl 1988;449:115-7. (Pubitemid 19004772)
24. Aronson AE, De Santo LW. Adductor spastic dysphonia: three years after recurrent laryngeal nerve resection. Laryngoscope 1983;93:1-8. (Pubitemid 13221690)
25. Biller HF, Som ML, Lawson W. Laryngeal nerve crush for spastic dysphonia. Ann Otol Rhinol Laryngol 1983;92:469. (Pubitemid 13021345)
26. Fritzell B, Feuer E, Haglund S, Knutsson E, Schiratzki H. Experiences with recurrent laryngeal nerve section for spastic dysphonia. Folia Phoniatr (Basel) 1982;34:160-7. (Pubitemid 12032362)
27. Sercarz JA, Berke GS, Ming Y, Rothschiller J, Graves MC. Bilateral thyroarytenoid denervation: a new treatment for laryngeal hyperadduction disorders studied in the canine. Otolaryngol Head Neck Surg 1992;107:657-68.
28. Fritzell B, Hammarberg B, Schiratzki H, Haglund S, Knutsson E, Mårtensson A. Long-term results of recurrent laryngeal nerve resection for adductor spasmodic dysphonia. J Voice 1993;7:172-8. (Pubitemid 23146574)
29. Allegretto M, Morrison M, Rammage L, Lau DP. Selective denervation: reinnervation for the control of adductor spasmodic dysphonia. J Otolaryngol 2003;32:185-9. (Pubitemid 37064175)
30. Berke GS, Blackwell KE, Gerratt BR, Verneil A, Jackson KS, Sercarz JA. Selective laryngeal adductor denervationreinnervation: a new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1999;108:227-31. (Pubitemid 29135927)
31. Chhetri DK, Mendelsohn AH, Blumin JH, Berke GS. Long-term follow-up results of selective laryngeal adductor denervation-reinnervation surgery for adductor spasmodic dysphonia. Laryngoscope 2006;116:635-42. (Pubitemid 44318078)
32. Blitzer A. Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol 2010;17(suppl 1):28-30.
33. Brin MF, Fahn S, Blitzer A, Ramig LO, Stewart C. Movement disorders of the larynx. In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris KS, eds. Neurologic disorders of the larynx. New York, NY: Thieme Medical Publishers, 1992:248-78.
34. Cannito MP, Woodson GE, Murry T, Bender B. Perceptual analyses of spasmodic dysphonia before and after treatment. Arch Otolaryngol Head Neck Surg 2004;130:1393-9. (Pubitemid 39603301)
35. Woodson GE, Zwirner P, Murry T, Swenson M. Use of flexible fiberoptic laryngoscopy to assess patients with spasmodic dysphonia. J Voice 1991;5:85-91.
36. Zwirner P, Murry T, Woodson GE. Perceptual-acoustic relationships in spasmodic dysphonia. J Voice 1993;7:165-71. (Pubitemid 23146573)
37. Roy N, Merrill RM, Gray SD, Smith EM. Voice disorders in the general population: prevalence, risk factors, and occupational impact. Laryngoscope 2005;115:1988-95. (Pubitemid 44391662)
38. Roy N, Merrill RM, Thibeault S, Gray SD, Smith EM. Voice disorders in teachers and the general population: effects on work performance, attendance, and future career choices. J Speech Lang Hear Res 2004;47:542-51. (Pubitemid 38900359)
39. Roy N, Merrill RM, Thibeault S, Parsa RA, Gray SD, Smith EM. Prevalence of voice disorders in teachers and the general population. J Speech Lang Hear Res 2004;47:281-93. (Pubitemid 38544549)
40. Roy N, Stemple J, Merrill RM, Thomas L. Epidemiology of voice disorders in the elderly: preliminary findings. Laryngoscope 2007;117:628-33.
41. Hogikyan ND, Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 1999;13:557-69. (Pubitemid 30007814)
42. Weinberger M, Oddone EZ, Samsa GP, Landsman PB. Are health-related quality-of-life measures affected by the mode of administration? J Clin Epidemiol 1996;49:135-40.
43. Le KD, Nilsen B, Dietrichs E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003;61:1294-6. (Pubitemid 37377561)
44. Ludlow CL, Adler CH, Berke GS, et al. Research priorities in spasmodic dysphonia. Otolaryngol Head Neck Surg 2008;139:495-505.
45. Schwartz SR, Cohen SM, Dailey SH, et al. Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg 2009;141(suppl 2):S1-S31.
46. Sulica L, Louis ED. Clinical characteristics of essential voice tremor: a study of 34 cases. Laryngoscope 2010;120:516-28.
47. Louis ED, Ford B, Barnes LF. Clinical subtypes of essential tremor. Arch Neurol 2000;57:1194-8. (Pubitemid 30644668)
48. Aronson AE, Hartman DE. Adductor spastic dysphonia as a sign of essential (voice) tremor. J Speech Hear Disord 1981;46:52-8. (Pubitemid 11100197)
49. Blitzer A, Brin MF, Fahn S, Lovelace RE. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988;98:636-40.
50. Kendall KA, Leonard RJ. Interarytenoid muscle Botox injection for treatment of adductor spasmodic dysphonia with vocal tremor. J Voice 2011;25:114-9.
51. Schweinfurth JM, Billante M, Courey MS. Risk factors and demographics in patients with spasmodic dysphonia. Laryngoscope 2002;112:220-3. (Pubitemid 34135862)